多发性硬化
原位
抗原
医学
临床孤立综合征
癌症研究
抗原提呈细胞
免疫学
原位杂交
体外
细胞培养
免疫系统
化学
生物
细胞
分子生物学
B细胞
CD40
作者
Chongdeng Shi,Maosen Han,Hui Yang,Xiaotian Zhao,Zuolin Zheng,Huijun Wang,Zhipeng Fu,Kuan Dai,Kun Zhao,Na Li,Yudong Song,Chen Chen,Fei Yang,Anning Li,Xinyi Jiang
标识
DOI:10.1016/j.apsb.2026.03.033
摘要
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Epstein‒Barr virus (EBV)-induced B-cell overactivation could lead to inflammatory injury to the CNS, which is thought to underlie the initiation and progression of MS. To specifically eradicate these B cells, we report in situ EBNA1-specific chimeric antigen receptor (CAR)-T cells that were transiently programmed with circular RNA (circRNA)-laden CD7-targeted lipid nanoparticles (CD7-LNP). We demonstrate that systematic injection of CD7-LNP can efficiently introduce CAR circRNA to T lymphocytes and yield in vivo CAR-T cells. These in situ CAR-T cells were able to specifically clear EBNA1-specific B cells and significantly mitigate the progression of MS in a MS mouse model. Thus, in situ generation of EBNA1-specific CAR-T cells hold promise as a therapeutic strategy for MS that avoids the risks of general immunosuppression, and warrant further clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI